BusinessOtonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis ExternaBy Nasdaq OMXJan 5, 2017, 12:01 PM UTC
BusinessCempra Receives Complete Response Letter From FDA For Solithromycin NDAsBy Nasdaq OMXDec 29, 2016, 11:55 AM UTC
BusinessCempra Appoints Dr. David Zaccardelli as Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to PresidentBy Nasdaq OMXDec 12, 2016, 2:01 PM UTC
BusinessToyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) Begins Phase 3 Studies in Japan With Cempra’s SolithromycinBy Nasdaq OMXDec 5, 2016, 1:01 PM UTC
BusinessOtonomy to Present at Piper Jaffray Healthcare ConferenceBy Nasdaq OMXNov 22, 2016, 9:05 PM UTC
BusinessFDA Advisory Committee Votes That Efficacy Results of Cempra’s Solithromycin Outweigh Risks for Community-Acquired Bacterial PneumoniaBy Nasdaq OMXNov 5, 2016, 2:40 AM UTC
